New migraine drugs are competitively pushing to receive reimbursement listing in Korea.

Following Lilly’s ‘Emgality (galcanezumab)’ in May, Ildong Pharmamceutical’s ‘'Reyvow (lasmiditan)’ has also passed deliberations by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee (DREC) on the 7th.

With Emgality already in pricing negotiations with the National Health Insurance Service, Il Dong is also working to speed up the listing process for Reyvow. Also, Teva-Handok’s new migraine drug ‘Ajovy’ is being reviewed for reimbursement adequacy.

The industry analysis is that all 3 new migraine drugs may be reimbursed wit